[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiotherapy-side-effect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiotherapy-side-effect":659},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,45,84,112,134,166,193,216,245,271,296,320,343,368,393,423,446,475,496,519,540,563,594,619,638],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100430810",false,"NCT04889924","ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer","Axillary Lymph Node Dissection Versus Axillary Radiotherapy in Breast Cancer Patients With Positive Sentinel Node After Neoadjuvant Therapy: A Multicenter Randomized Study","ADARNAT","Inclusion Criteria:\n\n* T1-T4 N0\u002F T0-T4 N1 at diagnosis and subsidiary of neoadjuvant treatment\n* Post-CT SLN with ≤2 macrometastasis\u002Fmicrometastasis or ITCs\n* Post-CT axillary response by ultrasound or MRI\n* Complete at least 70% of neoadjuvant chemotherapy and 6 months of endocrine treatment.\n\nExclusion Criteria:\n\n* cN2\n* ypN0\n* History of breast surgery for ipsilateral cancer in the last 10 years\n* History of other cancer in the last 5 years, except squamous carcinoma of the skin.","ALL","18 Years",{"count":20,"type":21},820,"ESTIMATED","INTERVENTIONAL",[24],"NA","In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis and does significantly reduce the appearance of lymphedema. However, patients who have received neoadjuvant systemic treatment cannot benefit from this option, even though in the majority of those who have responded well to treatment, a residual disease in the armpit is low, but there are no studies yet published that supports the possibility of not performing lymphadenectomy.\n\nThe primary endpoint is to evaluate wether axillary radiotherapy (ART) presents a lower risk of lymphedema with respect to lymphadenectomy (ALND) in patients with breast cancer who, after neoadjuvant systemic treatment (NST), present the sentinel node affected. Likewise, we will evaluate recurrences and overall survival in both groups. Finally, we will analyze the quality of life of these patients.",[27,28,29,30,31],"Breast Cancer","Chemotherapy","Sentinel Lymph Node","Axillary Lymph Nodes Dissection","Radiotherapy Side Effect","RECRUITING","2026-05-18",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":36},"2021-06-11",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Hospital Universitari de Bellvitge","OTHER",60,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":56,"conditions":57,"keywords":67,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":52,"type":21},400,[54,55],"PHASE2","PHASE3","This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[58,59,60,61,28,62,31,63,64,65,66],"Rectal Cancer","Total Neoadjuvant Treatment","Neoadjuvant Therapy","Radiotherapy","Organ Preservation","Chemotherapy Side Effects","Chemoradiotherapy","Low Anterior Resection Syndrome","Quality of Life",[68,59,69,61,28,64,62,31,70,71,72,73,65],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications","2026-05-06",{"date":76,"type":36},"2026-05-11",{"date":78,"type":36},"2025-01-06",{"date":80,"type":21},"2029-12-27",{"name":82,"class":43},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",1,{"id":85,"slug":4,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":83},"100438208","NCT04986293","CPAP or BiPAP for Motion Mitigation During Radiotherapy","Continuous and Bi-level Positive Airway Pressure for Motion Mitigation of Intra-thoracic Tumors Treated With Radiotherapy","SISTER","Inclusion Criteria:\n\n* Age ≥18 years\n* Stage III\u002FIV (N)SCLC, esophageal cancer or malignant lymphoma that will be treated with curative intent\n* WHO 0-2.\n* Written informed consent\n\nExclusion Criteria:\n\n* Facial deformations so that facial mask is impossible to fit\n* Noncompliance with any of the inclusion criteria.\n* Planned for radiotherapy with fraction dose ≥3 Gy.\n* Severe heart failure (LVEF\\\u003C30%)",{"count":92,"type":21},31,[24],"When using highly conformal radiotherapy techniques, such as proton therapy, a controlled breathing pattern and a minimal breathing amplitude could greatly benefit the treatment of mobile tumors. This reduction in tumor motion may be achieved with the use of a ventilator that is able to regulate and modulate the breathing pattern. CPAP provides a constant level of positive airway pressure. Compared to spontaneous breathing, the use of CPAP increased lung volume and can result in a significant decrease in tumor movement and a significant decrease in both mean lung and mean heart radiation dose. These results were found in patients treated for limited stage disease, it is not clear if this approach is feasible for patients with more advanced stage of disease that undergo radiotherapy with curative intent.\n\nWith Bilevel Positive Airway Pressure (BiPAP), tidal volume excursions are determined by the pressure difference between the set inspiratory positive airway pressure (IPAP) and the set expiratory positive airway pressure (EPAP). This mode of ventilation increases lung volume comparable to CPAP, but also to control tidal volumes and breathing frequency. However, BiPAP has never been studied in the setting of motion mitigation during radiotherapy and BiPAP might be more difficult to adjust to for patients compared to CPAP. Therefore, the current study is proposed to evaluate whether or not CPAP or BiPAP is of benefit in patients that undergo radiotherapy for larger intra-thoracic tumor volumes.",[31,96,97,98],"NSCLC","Esophageal Cancer","Malignant Lymphoma",[100,101,102],"BiPAP","CPAP","Mechanical ventilation","2026-04-28",{"date":105,"type":36},"2026-05-04",{"date":107,"type":36},"2021-06-01",{"date":109,"type":21},"2027-12",{"name":111,"class":43},"University Medical Center Groningen",{"id":113,"slug":4,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":120,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100633565","NCT07528339","Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK)","PRIOR","Inclusion Criteria:\n\n* High dose reirradiation (reirradiation type I or II or repeat organ irradiation delivered with the aim of local control)\n\nRead Danish (for questionnaires + patient information)\n\nLife expectancy due to age and co-morbidity of ≥6 months.\n\nThe general condition must be sufficient to tolerate persistent significant side effects\n\nHistological or imaging verified loco-regional recurrence, solitary oligo metastasis or new primary\n\nAge ≥18 years\n\nSigned informed consent, updated annually\n\nExpected follow up physical, by video, by phone or likely contact at a relevant oncological department\n\nAvailable dose plan(s) from primary (and prior) radiotherapy course(s) (with 3D reconstruction of previous plans, available port film, or drawings). Multiple re-treatments are allowed (new inclusion and baseline registration)\n\nExclusion Criteria:\n\n* The primary and reirradiation treatments may not be quasi-simultaneous (i.e. the two treatments should be planned independently)\n\nInability to attend full course of radiotherapy\n\nPurpose of radiotherapy is ONLY palliation of symptoms",{"count":119,"type":21},500,"5 Years","OBSERVATIONAL","The study aims to provide a setup for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for all Danish cancer patients undergoing reirradiation with high dose intention or with the aim of local tumour control; with the ultimate aim of providing safe reirradiation to a larger group of patients. To build a reirradiation cohort database for future research",[31],"NOT_YET_RECRUITING","2026-04-07",{"date":127,"type":36},"2026-04-14",{"date":129,"type":21},"2026-04-01",{"date":131,"type":21},"2037-03-31",{"name":133,"class":43},"University of Aarhus",{"id":135,"slug":4,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":18,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":165},"100563633","NCT06618703","Brain Irradiation for Childhood Cancer - Endocrine Monitoring During the First Years","Endocrine Follow-up After Cerebral Radiotherapy Performed Before Age 16 (Direct Cerebral Field or Following Facial, Cervical or High Ear, Nose, and Throat Radiotherapy)","BIChE-1","Inclusion Criteria:\n\n* Patient aged 4 years or more (≥4) and less than 18 years (\\\u003C18) at inclusion\n* Treated with radiotherapy to part or all of the brain for cancer or hematological malignancy before age 16 (≤15)\n* Post-radiotherapy time less than or equal to 5 years (≤5)\n* In remission of this pathology at the end of oncological treatments, or, with stable residual disease without treatment for 2 years or more (≥2)\n* Signature of informed consent from parents or legal guardian\n* Patient affiliated to the social security system or beneficiary of such a system\n\nExclusion Criteria:\n\n* Patients who have relapsed or developed a second cancer with a post-treatment delay of \\\u003C 1 year\n* Patient in palliative situation\n* Brain irradiation with dosimetric data showing sparing of the hypothalamic-pituitary axis (Dmax hypothalamic-pituitary axis \\\u003C 15 Gy)\n* Patient with a known hypothalamic-pituitary axis endocrine deficit prior to radiotherapy\n* Refusal of child or parents","4 Years",{"count":143,"type":21},230,[24],"BICHE- 1: Brain Irradiation for Childhood cancer - Endocrine monitoring during the first five years is a study of endocrine monitoring after cerebral radiotherapy.\n\nThe study concerns patients in remission at the end of oncological treatment aged between 4 and 18 years at the time of inclusion and who have had radiotherapy before the age of 16, irradiating all or part of the brain, with a delay between the end of radiotherapy and inclusion of less than 5 years. Patients will be included during a routine visit to the paediatric endocrinologist.\n\nThe protocol for the Biche 1 study has been designed and discussed in a multidisciplinary and multicentre manner, based on data from the literature and the French reference document (September 2021) \"National protocol for diagnosis and care - congenital pituitary deficiency\".\n\nIn this population, the investigators will conduct a descriptive and exploratory study to establish recommendations for medium-term follow-up; to improve screening for endocrine deficiencies affecting the hypothalamic-pituitary axis in order to improve patients' quality of life and state of health; and to better define dose-volume constraints on the axis.\n\nThe study will also focus on better detection and characterisation of chronic fatigue as a potential sequela of pituitary deficiencies, in particular by means of a questionnaire assessing fatigue (PedsQL Multidimensional Fatigue scale) which will also be systematically administered and completed annually.The expected sample size is 100-150 patients treated for a brain tumour and 60-80 patients treated for another tumour but with an irradiation field covering all or part of the brain.",[147,148,31],"Endocrine; Deficiency","Hypothalamo-Pituitary Disorder",[150,151,152,153,154],"Hypothalamic-pituitary axis deficiency","cerebral radiotherapy","brain tumours","endocrine monitoring","follow-up protocol","2026-03-31",{"date":157,"type":36},"2026-04-06",{"date":159,"type":36},"2025-10-10",{"date":161,"type":21},"2030-10",{"name":163,"class":164},"University Hospital, Angers","OTHER_GOV",3,{"id":167,"slug":4,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":173,"targetDuration":174,"studyType":121,"phases":4,"briefSummary":175,"conditions":176,"keywords":181,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":83},"100589104","NCT06950073","Curatively Intended Thoracic Reirradiation","CUratively Intended Thoracic REirradiation: An Observational Study of High-dose Reirradiation of Thoracic Tumours: A Multicentre Prospective Registration Protocol","CureLung","Inclusion Criteria:\n\n* Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.\n* Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \\[Andratschke 2022\\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.\n* Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.\n* Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.\n* Adequate lung function to tolerate treatment, at the discretion of the treating physician.\n* Ability to complete a radiotherapy course with the aim of local control.\n* ECOG Performance status 0-2.\n* Estimated life expectancy ≥ 6 months\n* Age ≥18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uncontrolled other malignancy.\n* The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)\n* Pregnancy\n* Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.",{"count":119,"type":21},"10 Years","The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates. Existing studies are small lacking high-quality data, with no clear correlation between toxicity risk and delivered radiotherapy (RT) dose.\n\nThis Danish multicentre prospective cohort study aims to provide a framework for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for patients with thoracic cancer undergoing reirradiation; with the ultimate aim of providing safe reirradiation to more patients.\n\nAs a secondary aim, guidelines for dose accumulation and provisional constraints for the organs at risk will be used to establish a uniform treatment strategy for reirradiation.\n\nThe CURE Lung trial will provide high-impact, globally missing data. This project will ensure full utilization of and learning from the trial, adding SDM, PROMs, and modality referral to the trial. It will model the correlation between toxicity burden and doses, enabling individualized reRT with optimized dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.",[31,177,178,179,180],"Radiation Toxicity","Oncology","Lung Cancer","Thoracic Cancer",[182,183,184,185,179,178,177],"Reirradiation","Aarhus","Denmark","Thoracic cancer","2026-03-02",{"date":188,"type":36},"2026-03-04",{"date":159,"type":36},{"date":191,"type":21},"2035-05-01",{"name":133,"class":43},{"id":194,"slug":4,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100571375","NCT06719440","Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume","Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study","BELGICA","Inclusion Criteria:\n\n* Participants capable of giving informed consent\n* Age \\>= 18 y.o.\n* WHO performance status 0-2\n* Newly diagnosed glioblastoma (Histologically proven glioblastoma per WHO 2021 classification based on biopsy or resection )\n* Indication of chemoradiotherapy confirmed by multidisciplinary tumour board\n\nExclusion Criteria:\n\n* Participation in a competing trial\n* Known contraindication to undergo MRI scans",{"count":201,"type":21},347,[24],"The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life.\n\nThe glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments.\n\nRadiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the \"Clinical Target Volume\" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation.\n\nThe BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.",[205,31],"Glioblastoma","2026-02-24",{"date":208,"type":36},"2026-02-27",{"date":210,"type":36},"2025-05-12",{"date":212,"type":21},"2031-10",{"name":214,"class":43},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",23,{"id":217,"slug":4,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":232,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":243,"locationsCount":83},"100623398","NCT07396116","Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)","Preoperative Hypofractionated Radiotherapy Combined With Immunotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-02)","FUSION-02","Inclusion Criteria:\n\n* Diagnosis \\& Indication: Primary or recurrent abdominopelvic soft tissue sarcoma. Patients are deemed to have a high probability of R1\u002FR2 resection with upfront surgery and are confirmed to require radiotherapy following Multidisciplinary Team (MDT) discussion.\n* Target Volume: In cases of multifocal disease, all lesions must be safely encompassable within a single radiotherapy target volume.\n* Age: Age ≥ 18 years.\n* Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status 0-2; American Society of Anesthesiologists (ASA) score ≤ 2; patients must be expected to tolerate surgery and radiotherapy.\n* Pathology: Histologically confirmed soft tissue sarcoma.\n* Measurability: Presence of evaluable lesions.\n* Life Expectancy: Life expectancy \\> 5 years.\n* Hematological \\& Hepatic Function: Adequate organ function\n* Renal Function: Adequate renal function defined as Glomerular Filtration Rate (GFR) ≥ 50 ml\u002Fmin (calculated by Cockcroft-Gault formula), and split renal function imaging confirms function in the contralateral kidney.\n* Contraception: Female patients of childbearing potential, or male patients with female partners of childbearing potential, must agree to use effective contraception during the entire treatment period and for 6 months after the last dose.\n* Consent: Signed informed consent form.\n* Follow-up: Capable of complying with follow-up requirements.\n\nExclusion Criteria:\n\n* Significant Comorbidities: Patients with the following concurrent conditions: active hemorrhage, ulceration, intestinal perforation, intestinal obstruction, uncontrolled hypertension, cardiac insufficiency (NYHA Class III-IV), severe hepatic or renal dysfunction (Grade 4), mesenteric ischemia, or severe inflammatory bowel disease (IBD).\n* Excluded Histologies: Other pathological types, including Gastrointestinal Stromal Tumor (GIST), sarcomatoid carcinoma, sarcomas primarily treated with chemotherapy (e.g., rhabdomyosarcoma and PNET), desmoid fibromatosis, and benign tumors.\n* Unresectability: Tumor invasion into critical structures such as the liver, pancreatic head, or abdominal aorta, rendering the tumor deemed unresectable.\n* Prior Radiotherapy: History of prior radiotherapy to the same anatomical region.\n* Distant Metastasis: Presence of distant metastasis (M1) confirmed by comprehensive imaging\u002Fexamination within 4 weeks prior to enrollment.\n* Contraindications to Surgery\u002FProtocol: Presence of other severe medical comorbidities that contraindicate surgery or preclude participation in the study.\n* Planned Neoadjuvant Chemotherapy: Patients scheduled to receive (concurrent) neoadjuvant chemotherapy.\n* Recent Systemic Therapy: Receipt of chemotherapy or other systemic treatments within 4 weeks prior to enrollment.",{"count":224,"type":21},28,[24],"To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy combined with immunotherapy followed by surgery for retroperitoneal sarcoma",[228,229,230,31,231],"Soft Tissue Sarcoma (STS)","Retroperitoneal Sarcoma","Immunotherapy","Ultra-hypofractionated Radiotherapy",[233,234,235,236,237],"hypofractionated radiotherapy","retroperitoneal sarcoma","soft tissue sarcoma","immunotherapy","peri-operative complications","2026-02-10",{"date":240,"type":36},"2026-02-12",{"date":240,"type":21},{"date":40,"type":21},{"name":244,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":246,"slug":4,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":252,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100624340","NCT07408362","Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies","How to Improve Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Chemotherapy and\u002For Thoracic Radiotherapy? Multimodal Cardiological Evaluation and Biomarkers.","CTRCT-pedia","Inclusion Criteria:\n\n* History of chemotherapy and\u002For radiotherapy for an oncological condition or bone marrow transplantation (hematologic disease) after 01\u002F01\u002F2016.\n* Age \\\u003C 18 years at the time of treatment.\n* Cancer remission for more than one year.\n* Voluntary participation following comprehensive informed consent.\n* Signed informed consent from the patient (≥ 18 years) or from parents\u002Flegal guardians, with signed assent for minors aged 8 to 17.\n\nExclusion Criteria:\n\n* Active disease recurrence or relapse.\n* Current administration of antineoplastic therapy.\n* Withdrawal of consent or refusal to participate by the patient or their legal representatives.","2 Years","25 Years",{"count":255,"type":21},100,[24],"The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy\u002Fthoracic radiotherapy). The main questions it aims to answer are:\n\n* Can advanced echocardiography (including strain and myocardial work), ECG, and ergospirometry effectively diagnose earlier subclinical cardiac impairment in this population?\n* What is the prevalence of cardiovascular risk factors (including physical activity levels and biological markers like proBNP\u002Ftroponins)\n* Can new genetic or biological markers be identified to help optimizing the detection of CTRCT?\n\nAt time of follow-up, if they agree, participants will:\n\n* Complete validated questionnaires regarding quality of life, physical activity, and sedentary behavior.\n* Undergo a cardiopulmonary exercise test (ergospirometry) for those aged over 8 years.\n* Wear an accelerometer (ActiGraph GT3X) for 7 consecutive days to monitor physical activity.\n* Provide an additional blood sample during routine follow-up for the creation of a biobank dedicated to analyzing markers of senescence, fibrosis, apoptosis, and genetic polymorphisms.",[259,260,261,31,262],"Cancer Therapy-related Cardiovascular Toxicity","Childhood Cancer","Chemotherapeutic Toxicity","Cardiovascular Complication",{"date":264,"type":36},"2026-02-13",{"date":266,"type":21},"2026-02-15",{"date":268,"type":21},"2033-12-31",{"name":270,"class":43},"Centre Hospitalier Universitaire de Liege",{"id":272,"slug":4,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":165},"100538981","NCT06297902","RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3","RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3 Randomized, Multicentre, Phase II Trial","RADPAINT-3","Inclusion Criteria:\n\n1. Histologically or cytologically verified invasive squamous cell carcinoma of the head and neck region; Sinonasal cancer, oral cavity cancer, hypopharynx cancer, larynx cancer, HPV negative oropharyngeal cancer and T4 (any N) HPV positive oropharyngeal cancer.\n2. Patients planned for standard curative RT (with or without concomitant chemotherapy \\[cisplatin, or cetuximab\\], with or without nimorazole hypoxic cell radiosensitizer)\n3. Age \\> 18 years\n4. WHO performance status 0-2\n5. Signed informed consent\n6. Ability to understand information about the study and to complete questionnaires\n\nExclusion Criteria:\n\n1. All diagnoses, cT1 cN0-N1 cM0\n2. Glottic cancer cT1-T2 cN0 cM0\n3. HPV positive oropharyngeal carcinoma T1-T3 (any N)\n4. Diabetes mellitus\n5. Use of anticoagulant medication\n6. Active smoking and\u002For alcohol abuse",{"count":255,"type":21},[24],"The objective of the RADPAINT-3 trial is to investigate whether dose painting is safe compared to standard radiotherapy. RADPAINT-3 is a randomized, non-inferiority, multi-center phase II study, initiated at the Section for Head and Neck Cancer, Department of Oncology, Oslo University Hospital, accruing from first half of 2024. The primary endpoint is frequency of grade ≥ 3 (CTCAE v5.0) mucosal ulcers one year after treatment. The expected inclusion period is three years, total study duration is six years and planned inclusion number is 100 patients. The collaborating sites are St Olav´s Hospital and Haukeland University Hospital. The patients will be randomized 1:1 to either standard radiotherapy (2 Gy x 34; total dose 68 Gy) or experimental radiotherapy (dose painting). All patients will have 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission computed tomography (FDG-PET\u002FCT) prior to radiotherapy. In the experimental arm, we will escalate the dose to the hypermetabolic part of the tumor (maximum point dose 83.3 Gy), shown in pre-treatment FDG-PET images. Dose escalation will be applied to these regions during the first half of the fractionated treatment (17 of 34 fractions). The patients in both arms will receive concomitant nimorazole (hypoxic radiosensitizer) and concomitant cisplatin if indicated according to standard treatment. The main inclusion criterion is patients with human-papillomavirus (HPV)-unrelated head and neck cancer with poor prognosis.\n\nThe RADPAINT-3 trial includes a translational sub-study where we aim to elucidate underlying mechanisms related to the radiotherapy effect, by investigating blood samples. Analysis of cytokines in repetitive blood samples may predict both tumor response and toxicity. The data derived from this sub-study, will be further explored using artificial intelligence.\n\nIf RADPAINT-3 shows that there is no excess toxicity, we will continue the study after a new protocol has been approved. The new primary endpoint will be local control at 1 year after radiotherapy. Power analysis show that we will need in total 182 evaluable patients including the 100 patients from RADPAINT-3. The translational sub-study will then be extended to investigate genetic expression data from pre-therapy routine tumor biopsies and correlate this with the analysis of blood samples and tumor control.",[282,31],"Head and Neck Cancer",[284,285,286,61],"Dose painting","18F-FDG","Positron emission tomography","2026-01-19",{"date":289,"type":36},"2026-01-21",{"date":291,"type":36},"2024-08-19",{"date":293,"type":21},"2030-06",{"name":295,"class":43},"Oslo University Hospital",{"id":297,"slug":4,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":310,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":83},"100456541","NCT05224934","Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)","Full-target Ultra-hypofractionated Stereotactic Irradiation Orchestrated With Nodule Boost for Retroperitoneal Sarcoma","FUSION-01","Inclusion Criteria:\n\n* Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis\n* Sarcoma not originated from bone structure, abdominal or gynecological viscera\n* All disease can be included safely within one radiotherapy field\n* Absence of extension through the sciatic notch or across the diaphragm\n* Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma\n* ECOG performance status 0 to 2\n* American Society of Anesthesiologist (ASA) score ≤2\n* Normal renal function: Calculated Creatinine Clearance ≥50ml\u002Fmin（by Cockcroft-Gault formula）and functional contralateral kidney by differential renal isotope scan\n* Normal bone marrow and hepatic function.\n* Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age\n* expected life expectancy longer than 5 years\n* Written consent form was given prior to treatment\n* Can safely be treated by radiotherapy and surgery\n\nExclusion Criteria:\n\n* metastatic disease\n* Tumor was previously treated by radiotherapy\n* Involvement of liver, pancreatic head or duodenum",{"count":304,"type":21},50,[24],"To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma",[308,229,31,231,309],"Soft Tissue Sarcoma","Stereotactic Ablative Radiotherapy",[311,233,234,235,237],"stereotactic ablative radiotherapy","2025-12-04",{"date":314,"type":36},"2025-12-11",{"date":316,"type":36},"2022-01-01",{"date":318,"type":21},"2027-12-31",{"name":244,"class":43},{"id":321,"slug":4,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":327,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":342,"locationsCount":83},"100453325","NCT05183074","MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)","Phase II Prospective Trial of MR-linac Based Stereotactic Ablative Radiotherapy for Patients With Localized (SAMRT-P01) and Oligo-metastatic (SMART-P02) Prostate Cancer","SMART-P01\u002F02","Inclusion Criteria:\n\n* Age≥18 years。\n* Histology confirmed prostate cancer.\n* Risk stratification, localised disease including patients with low-risk(cT1-T2a，PSA \\\u003C10ng\u002FmL，Gleason score≤6) who refuse active surveillance, favorable or unfavorable intermediate-risk and selected high-risk(cT2b-T3a or minimally T3b，PSA 10-40ng\u002FmL，Gleason score 7-8) disease.\n* Oligo-metastatic disease including patients with prostate in-situ and oligometastatic disease (no limit to mets number and organs, with all metastatic foci can be safely treated by radical SBRT dose)\n* ECOG 0-2\n* Postate gland volume ≤100cc\n* IPSS score of \\\u003C18\n* Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed\n\nExclusion Criteria:\n\n* Contraindications to MRI.\n* TURP within the past 6 months\n* Ulcerative colitis, Crohn's Disease, ataxia telangiectasia, or systemic lupus erythematosus\n* Previous pelvic irradiation\n* Refuse contraception","MALE",{"count":304,"type":21},[24],"1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer\n2. To assess the acute and late toxicities, efficacy and quality of life for patients treated by MRL-SBRT\n3. To simulate the dose planning and assess the feasibility of simultaneous-boost for MR-prominent foci\n4. To investigate the relationship between the changes of blood and tissue biomarkers and manifestations on mp-MRI pre-\u002Fpost-MRL-SBRT, to further ascertain the predictive factors of local persisting and\u002For relapse disease",[332,31,333,334,335,336,337],"Prostate Cancer","Magnetic Resonance-linac","Stereotactic Ablative RT","Adaptive Radiotherapy","Localised Disease","Oligometastatic Disease",{"date":314,"type":36},{"date":340,"type":36},"2021-02-01",{"date":318,"type":21},{"name":244,"class":43},{"id":344,"slug":4,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":358,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":83},"100609483","NCT07215169","Manual Lymph Drainage for External Lymphedema","The Effect of Manual Lymph Drainage for Cancer Treatment-related External Lymphedema in the Head and Neck - a Pilot and Feasibility Study of a Randomized Controlled Trial","MLD-HN","Inclusion Criteria:\n\n* • a previous diagnosis of oropharyngeal cancer (all histological types are accepted)\n\n  * curative treatment with (chemo)radiotherapy to at least 68Gy at the primary site completed no more than 1 year before the study inclusion\n  * age \\>18 years\n  * ability to give written and informed consent.\n\nExclusion Criteria:\n\n* • pregnancy\n\n  * surgery or Botox injections in the tissue of the head and neck area\n  * Locoregional deep infection i.e., suspected abscess at the scheduled time points for measurements.\n  * prior daily treatment with Self MLD\n  * other treatment of head and neck lymphedema, for example compression\n  * psychiatric disorders\n  * substance abuse problems",{"count":351,"type":21},40,[24],"This study will evaluate the feasibility of a randomized controlled trial. The future randomized controlled trial will compare two groups following different intensities of manual lymphatic drainage for external head- and neck lymphedema among persons treated with radiotherapy for head- and neck cancer.",[355,356,31,357],"Lymphedema of Face","Neoplasms","Lymphedema Due to Radiation",[359],"Head and neck lymphedema management","2025-10-02",{"date":159,"type":36},{"date":363,"type":36},"2025-10-01",{"date":365,"type":21},"2027-06",{"name":367,"class":43},"Lund University",{"id":369,"slug":4,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100607516","NCT07189572","Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma","Efficacy of Intranasal Corticosteroid Spray in Preventing Otitis Media With Effusion After Radiotherapy for Nasopharyngeal Carcinoma: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Pathologically confirmed nasopharyngeal carcinoma scheduled for curative intensity-modulated radiation therapy (IMRT), with or without concurrent chemotherapy.\n* Age between 18 and 75 years.\n* No previous history of head and neck radiotherapy.\n* Intact tympanic membranes bilaterally at baseline, with no history of middle ear surgery (including tympanostomy tube placement).\n* Willing to comply with all study procedures, including nasal spray use, audiological examinations, and follow-up visits.\n* No use of systemic or topical corticosteroids, antihistamines, or decongestants within 14 days prior to randomization.\n* All inclusion criteria must be met for participation\n\nExclusion Criteria:\n\n* Diagnosed with complete conductive hearing loss or ossicular chain fixation.\n* Scheduled to undergo tympanostomy tube placement, tympanotomy, or other middle ear surgery prior to randomization.\n* Unlikely to complete the 12-month follow-up (e.g., planned relocation, poor compliance).\n* Presence of respiratory conditions requiring treatment with nasal corticosteroids.\n* Known allergy or hypersensitivity to nasal corticosteroids (especially triamcinolone acetonide or its excipients).\n* History of severe mental illness, cognitive impairment, or substance abuse that may affect compliance.\n* Pregnant or lactating women, or women of childbearing potential unwilling to use effective contraception.\n* Participation in other investigational drug clinical trials within the past 3 months.\n* Deemed unsuitable for the trial by the investigator (e.g., severe septal deviation, chronic rhinosinusitis requiring systemic treatment, or poorly controlled diabetes).\n* Any subject who meets any of the above exclusion criteria at baseline will be excluded from the study.","75 Years",{"count":376,"type":21},168,[55],"This study focuses on a common side effect experienced by many patients after radiation therapy for nasopharyngeal cancer, which is a type of head and neck cancer. This side effect is called secretory otitis media (fluid buildup in the middle ear). It can cause a feeling of fullness in the ear and hearing loss. While procedures like ear tube placement can help, they can also lead to other problems like ear infections and drainage.\n\nRadiation treatment is thought to cause inflammation that disrupts the normal function of the tube connecting the ear to the throat (Eustachian tube), leading to this fluid buildup. A nasal spray containing a steroid medicine (triamcinolone acetonide) is already known to be safe and effective at reducing inflammation in the ear fluid of both children and adults. We believe that using this spray may also help prevent and improve this condition in nasopharyngeal cancer patients after radiation therapy.\n\nThe main goal of this study is to explore whether this nasal spray can effectively prevent or reduce fluid buildup in the ear following radiation therapy. We hope this non-invasive treatment will provide a new option to improve the quality of life for these patients.",[380,381,382,31,383],"Otitis Media","Otitis Media With Effusion After Nasopharyngeal Carcinoma","Radiotherapy Side Effects","Otitis Media With Effusion (OME)","2025-09-23",{"date":386,"type":36},"2025-09-29",{"date":388,"type":21},"2025-10",{"date":390,"type":21},"2027-10",{"name":392,"class":43},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":400,"sex":327,"minAge":18,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":410,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":83},"100499706","NCT05786742","Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.","ULTRA-HYPO Fractionated (UHF) Compared to Moderate-HYPO Fractionated (MHF) Prostate IGRT With HDR Brachytherapy BOOST : A Phase 1-2 Study.","HYPO-5","Inclusion Criteria:\n\n* Biopsy proven Prostate adenocarcinoma\n* Stage T1c, T2 (Annex 2)\n* Stage Nx or N0\n* Stage Mx or M0\n* PSA \\\u003C 20ng\u002Fml\n* Gleason Score 6 or 7\n* Having the ability to sing a written consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18ans\n* Clinical Stage T3 or T4\n* Stage N1\n* Stage M1\n* PSA \\> 20\n* Gleason Score 8 to 10\n* IPSS Score \\> 20 alpha-blocking medication.\n* Prior pelvic radiotherapy.\n* History of active collagenosis (Lupus, Sclerodermia, Dermatomyosis)\n* Past history of Inflammatory Bowell Disease\n* Bilateral hip prosthesis",true,"95 Years",{"count":403,"type":21},205,[24],"Phase 1-2 study, comparing ultra-hypofractionnated (UH) to a moderately hypofractionnated (MH) radiation therapy, with image guided HDR prostate brachytherapy. Using iso-equivalent doses, a non-inferiority analysis will be done in order to prove UH non-inferior to MH, toxicity wise. Acceptability, tolerability, acute and late toxicity will be reported. MRI visible dominant intra-prostatic lesion will be outlines and variability between radiation oncologists and radiologists will be reported. As secondary objective, biochemical and clinical failure free survival will be reported at 5 \\& 10 years.",[332,31,407,408,61,409],"Hypofractionation","Brachytherapy","Localized Prostate Carcinoma",[411,412,413],"hypo fractionation","brachytherapy","Ultra Hypo fractionation","2025-09-07",{"date":416,"type":36},"2025-09-09",{"date":418,"type":36},"2014-04",{"date":420,"type":21},"2033-12",{"name":422,"class":43},"CHU de Quebec-Universite Laval",{"id":424,"slug":4,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":4},"100602900","NCT07129525","Health Oriented Protocol for Epidermal Radiodermatitis","Health Oriented Protocol for Epidermal Radiodermatitis,A Prospective Observational Study","HOPE","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* with head and neck or pelvic malignancies\n* undergoing either exclusive radiotherapy or concurrent chemoradiotherapy will be included, following signed informed consent.\n\nExclusion Criteria:\n\n* Pediatric patients,\n* patients with malignancies outside the head and neck or pelvic regions,\n* patients who have not yet started or have already completed exclusive radiotherapy or concurrent chemoradiotherapy",{"count":431,"type":21},80,"Radiation therapy is a standard treatment for malignant tumors of the head and neck and pelvic regions, used alone or in combination with chemotherapy. While effective, it is often associated with adverse effects that can impact patient outcomes. Among the most frequent toxicities is radiation-induced dermatitis (RID), affecting up to 95% of patients. These skin reactions, ranging in severity, may compromise quality of life and lead to treatment interruptions.The severity of RID is influenced by both intrinsic and extrinsic factors. Intrinsic factors include age, sex, ethnicity, nutritional status, and comorbidities such as diabetes or systemic inflammation. Extrinsic factors include the radiation technique, total dose, treated volume, and presence of infections. These variables require close monitoring to reduce complications.Radiation damages the skin and underlying tissues, causing xerosis, pigmentation changes, loss of elasticity, fibrosis, and varying degrees of dermatitis. Effective prevention starts with patient education and skincare support throughout treatment to reduce incidence and severity.In Italy, head and neck cancers, though less common than other malignancies, present a significant clinical burden. Laryngeal cancer accounts for around 5,000 new cases annually. Oral cavity, pharyngeal, and thyroid tumors also have notable incidence and require complex treatments such as (chemo)radiotherapy, increasing the risk of RID.RID represents not only a clinical issue but also a psychological and functional challenge. Pain, emotional distress, and reduced autonomy are key aspects affecting patients' overall wellbeing. A multidimensional approach that integrates clinical care and psychosocial support is essential.This study aims to investigate the relationship between RID severity, pain, psychological distress, and functional autonomy during radiotherapy or chemoradiotherapy, identifying predictors of severe toxicity and guiding personalized supportive care.",[282,434,435,436,31],"Pelvic Cancer","Radiation Skin Injury","Gynecologic Cancer","2025-08-11",{"date":439,"type":36},"2025-08-19",{"date":441,"type":21},"2025-09",{"date":443,"type":21},"2026-09-30",{"name":445,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":452,"targetDuration":454,"studyType":121,"phases":4,"briefSummary":455,"conditions":456,"keywords":460,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":83},"100454877","NCT05203250","Longitudinal Registry Including Patients Treated With Heavy Particles","CNAO REgistry triAL - REGAL","Inclusion Criteria:\n\n* Patients treated with heavy particles at Fondazione CNAO, Pavia\n* Patients who have the ability to understand and be willing to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients or legal guardians who are unable to understand informed consent document",{"count":453,"type":21},3000,"50 Years","The purpose of this registry is to collect retrospective and prospective standardized data of patients treated with particle therapy, either with protons or carbon ions, at the National Center for Oncological Hadrontherapy (CNAO) based in Pavia.\n\nBy keeping track of the patients treated, it will allow the investigators to periodically analyze and evaluate data collected of daily clinical activity. This will help gathering more information on the results of particle therapy and will provide the basis for in depth evaluation of patients' outcome with respect to the delivered treatment.",[457,178,458,31,177,459],"Cancer","Radiation Exposure","Rare Disease",[461,178,457,61,462,463,464,465],"Hadrontherapy","Protons","Carbon Ions","Heavy ions","Rare cancer","2025-08-01",{"date":468,"type":36},"2025-08-06",{"date":470,"type":36},"2021-06-04",{"date":472,"type":21},"2071-06-04",{"name":474,"class":43},"CNAO National Center of Oncological Hadrontherapy",{"id":476,"slug":4,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":482,"minAge":18,"maxAge":483,"enrollmentInfo":484,"targetDuration":252,"studyType":121,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":83},"100498861","NCT05775757","SMC Radiation Oncology Breast Cancer Cohort Study","Registry for Analysis of Impact of Radiation Dose to Skin on Cosmetic Outcome and Patient-reported Outcomes in Patients With Breast Cancer Treated With Radiation Therapy","RASCO","Inclusion Criteria:\n\n* Breast cancer treated with curative surgery\n\nExclusion Criteria:\n\n* History of thoracic radiation therapy","FEMALE","85 Years",{"count":119,"type":21},"The goal of this observational study is to learn about toxicities and cosmetic outcomes in breast cancer patients treated with hypofractionated radiotherapy.\n\nThe main question it aims to answer are:\n\n* Changes in breast skin\n* Factors related to breast skin changes\n* Patient-reported outcomes\n* Cosmetic outcomes\n\nParticipants will be assessed by multi-dimensional methods before and after radiotherapy:\n\n* Photographs\n* Fibrometer\n* Questionnaires (BREAST-Q)\n* CTCAE version 4.03 evaluated by treating physicians",[31],"2025-06-27",{"date":489,"type":36},"2025-06-29",{"date":491,"type":36},"2021-01-01",{"date":493,"type":21},"2030-12-31",{"name":495,"class":43},"Samsung Medical Center",{"id":497,"slug":4,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":17,"minAge":374,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":22,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":83},"100540064","NCT06311981","Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","A Prospective Phase II Clinical Study of Carbon Ion Radiotherapy for Locally Advanced Non-small Cell Lung Cancer in the Older Adult","Inclusion Criteria:\n\n* Older than 75 years old.\n* ECOG general status score of 0-2.\n* Primary non-small cell lung cancer (NSCLC) confirmed by histology or cytological pathology, T1-4N1-3M0, stage IIb-IIIc (AJCC\u002FUICC 8th edition).\n* Medically inoperable, or patient refuses surgery.\n* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109\u002FL, platelet count ≥80 x 109\u002FL, hemoglobin ≥9 g\u002FdL 2). Lung function: FEV1\\>25%, DLCO\\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \\\u003C1.5 times the upper limit of normal value, and AST, ALT\\\u003C2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml \u002Fmin, and urinary protein \\\u003C2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Patient with squamous cell carcinoma was treated with bevacizumab before carbon ion radiotherapy.\n* Complicated with other malignant tumors that have not been controlled.\n* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.\n* Chest radiation therapy or radioactive particle implantation history.\n* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.\n* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.\n* A history of mental illness may hinder the completion of treatment.\n* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.\n* Other circumstances that the physician considers inappropriate to participate in clinical study.",{"count":503,"type":21},29,[54],"To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.",[507,508,509,31],"Non-small Cell Lung Cancer","Older People","Carbon Ion Radiotherapy","2025-06-10",{"date":512,"type":36},"2025-06-13",{"date":514,"type":36},"2024-08-08",{"date":516,"type":21},"2026-06-17",{"name":518,"class":43},"Jian Chen",{"id":520,"slug":4,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":22,"phases":528,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":83},"100540062","NCT06311955","Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor","Prospective Phase II Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymic Epithelial Malignant Tumor Received R2 Resection","Inclusion Criteria:\n\n* Patients with stage II-IV (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiotherapy who had undergone radical surgery (R2 resection, visible residual tumor) and had a definite pathological diagnosis.\n* Sign informed consent.\n* Between the ages of 18 and 70.\n* ECOG general status score of 0-2.\n* The expected survival is at least 6 months.\n* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109\u002FL, platelet count ≥80 x 109\u002FL, hemoglobin ≥9 g\u002FdL 2). Lung function: FEV1\\>25%, DLCO\\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \\\u003C1.5 times the upper limit of normal value, and AST, ALT\\\u003C2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml \u002Fmin, and urinary protein \\\u003C2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.\n\nExclusion Criteria:\n\n* Complicated with other malignant tumors that have not been controlled.\n* Have large quantity of pleural or pericardial effusion.\n* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.\n* Chest radiation therapy or radioactive particle implantation history.\n* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.\n* Pregnancy (confirmed by serum or urine β-HCG test) or lactation period.\n* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.\n* A history of mental illness may hinder the completion of treatment.\n* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.\n* Other circumstances that the physician considers inappropriate to participate in clinical study.","70 Years",{"count":527,"type":21},48,[54],"To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.",[531,31,532,533],"Thymic Epithelial Tumor","Carbon Ion Radiotheray","Heavy Ion Radiotherapy",{"date":512,"type":36},{"date":536,"type":21},"2025-07-01",{"date":538,"type":21},"2029-02-28",{"name":518,"class":43},{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":374,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":562},"100593613","NCT07008716","Omitting CTV for Primary Tumor in LS-SCLC","Omission of Clinical Target Volume (CTV) for Primary Tumors in Limited-Stage Small Cell Lung Cancer: A Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metastasis;\n2. Aged 18-75 years, KPS score ≥ 80, ≤ 10% weight loss within the past 6 months;\n3. Have measurable lesions per RECIST 1.1 criteria;\n4. Have no disease progression after 2-4 cycles of etoposide\u002Fcarboplatin or etoposide\u002Fcisplatin;\n5. Lung function test: FEV1 ≥ 1 L (Optional);\n6. Complete blood count: neutrophil count ≥ 1.5 x 10\\^9\u002FL, hemoglobin ≥ 100 g\u002FL, platelet count ≥ 100 x 10\\^9\u002FL;\n7. Renal function: serum creatinine ≤ 1.5 x upper limit of normal (ULN);\n8. Liver function: AST and ALT ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN;\n9. Fully understand the study, able to complete treatment and follow-up, and voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. Other malignant tumors (prior or concurrent), except those that have been curatively treated with disease-free survival ≥ 5 years, such as non-melanoma skin cancer, cervical carcinoma in situ, or early-stage papillary thyroid cancer;\n2. Uncontrolled heart disease or myocardial infarction within the past 6 months;\n3. Patients with a history of mental illness;\n4. Pregnant and lactating patients;\n5. Poorly controlled diabetes and hypertension;\n6. Interstitial pneumonia or active pulmonary fibrosis;\n7. Active infection;\n8. Other conditions unsuitable for enrollment (per investigator judgment).",{"count":547,"type":21},852,[55],"This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC). Patients in the experimental group would receive radiotherapy with omission of the clinical target volume (CTV) for the primary tumor, while those in the control group would receive radiotherapy including CTV. The efficacy and toxicity of the two groups are compared to provide evidence for the radiotherapy of LS-SCLC. The target volume of LS-SCLC may be reduced by omitting CTV without increasing local recurrence but potentially reducing the dose to organs at risk and the side effects.",[551,458,31,552],"SCLC, Limited Stage","Progression","2025-05-29",{"date":555,"type":36},"2025-06-06",{"date":557,"type":21},"2025-06-03",{"date":559,"type":21},"2032-12-31",{"name":561,"class":43},"Sun Yat-sen University",2,{"id":564,"slug":4,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":482,"minAge":18,"maxAge":570,"enrollmentInfo":571,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":573,"conditions":574,"keywords":579,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":83},"100539617","NCT06306170","Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)","Efficacy of Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)","GYN-ART","Inclusion Criteria:\n\n* gynecologic cancer patients\n* \\>18 years old\n* treated with advanced radiotherapy techniques (IGRT, IMRT, SBRT)\n\nExclusion Criteria:\n\n* other tumors\n* \\> 90 years old","90 Years",{"count":572,"type":21},1000,"This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- will be included and toxicity and outcomes analyzed.",[436,31,575,576,577,578],"Radiotherapy; Complications","Survivorship","Progression, Disease","Progression, Clinical",[436,580,581,582,583,584],"Image Guided Radiotherapy","PET\u002FCT","Intensity Modulated Radiotherapy","Stereotactic Body Radiotherapy","Oligometastases","2025-04-19",{"date":587,"type":36},"2025-04-22",{"date":589,"type":36},"2024-02-15",{"date":591,"type":21},"2029-02-15",{"name":593,"class":43},"IRCCS San Raffaele",{"id":595,"slug":4,"hasResults":11,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":525,"enrollmentInfo":601,"targetDuration":4,"studyType":22,"phases":603,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":83},"100573896","NCT06752239","Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC","Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in Nasopharyngeal Carcinoma (PROTECT-NPC): A Multicenter, Non-Inferiority, Open-Label, Randomized Controlled Phase III Clinical Trial","PROTECT-NPC","Inclusion Criteria:\n\n1\\. Male or female, aged 18-70 years; 2. Pathologically confirmed nasopharyngeal carcinoma; 3. No positive lymph nodes in unilateral or bilateral regions III and IVa; 4. Clinical stage I-IVa (AJCC\u002FUICC 8th edition), with no evidence of distant metastasis; 5. Normal thyroid function; 6. ECOG performance status of 0-1; 7. Treatment-naïve patients who have not received any prior antitumor therapy; 6. No contraindications to radiotherapy or chemotherapy; 9. Adequate organ function, meeting the following criteria: Hematologic criteria: WBC ≥ 4.0 × 10⁹\u002FL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL, HGB ≥ 90 g\u002FL (no transfusion, blood products, or hematopoietic growth factors used within the past 7 days); Biochemical criteria: ALT and AST \\\u003C 1.5 × ULN, ALP \\\u003C 2.5 × ULN, total bilirubin \\\u003C ULN, BUN and creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n\n10\\. Voluntarily agreed to participate in the study, signed the informed consent form, demonstrated good compliance, and agreed to follow-up.\n\nExclusion Criteria:\n\n1. History of other malignant tumors (excluding basal cell carcinoma\u002Fsquamous cell carcinoma of the skin or cervical carcinoma in situ);\n2. History of radiotherapy (excluding radiotherapy outside the planned target area for conditions such as melanoma);\n3. History of neck surgery;\n4. Any severe comorbidities that may pose risks to the study or affect compliance, such as unstable heart disease requiring treatment, kidney disease, chronic hepatitis, poorly controlled diabetes (fasting blood glucose \\> 1.5 × ULN), or psychiatric disorders;\n5. History of hyperthyroidism, hypothyroidism, or immune-related thyroid disorders;\n6. Other family or social factors, as judged by the investigator, may force the study's early termination, compromise patient safety, or affect the collection of trial data.",{"count":602,"type":21},474,[55],"This study is a multicenter, non-inferiority, open-label, randomized controlled Phase III clinical trial. It aims to compare the efficacy of modified delineation radiotherapy (experimental group) versus standard delineation radiotherapy (control group) in the prophylactic irradiation of neck lymphatic drainage areas III\u002FIVa in nasopharyngeal carcinoma. The study evaluates the incidence of primary hypothyroidism, quality of life, and adverse events between the two groups.",[606,66,607,31,61],"Nasopharyngeal Carcinoma","Thyroid Diseases",[606,66,609,61],"Thyroid Function Protection","2025-04-08",{"date":612,"type":36},"2025-04-10",{"date":614,"type":36},"2025-01-01",{"date":616,"type":21},"2031-12-31",{"name":618,"class":43},"Jiangxi Provincial Cancer Hospital",{"id":620,"slug":4,"hasResults":11,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":11,"sex":482,"minAge":18,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":637},"100498891","NCT05776147","Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study","RADIANT","Inclusion Criteria:\n\n* Women over 18 years old;\n* Diagnosis of breast cancer of any molecular subtype;\n* Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively;\n* Treated from December\u002F2019 onward;\n* With clinical and treatment data available in medical records.\n\nExclusion Criteria:\n\n* The protocol does not provide exclusion criteria.",{"count":52,"type":21},"The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.",[31],"2025-03-06",{"date":630,"type":36},"2025-03-07",{"date":632,"type":36},"2023-11-09",{"date":634,"type":21},"2025-06-01",{"name":636,"class":43},"Latin American Cooperative Oncology Group",11,{"id":639,"slug":4,"hasResults":11,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":11,"sex":327,"minAge":18,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":22,"phases":645,"briefSummary":646,"conditions":647,"keywords":648,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":658},"100466188","NCT05350475","Protons Vs. Photons for High-risk Prostate Cancer","Lymph Node Radiation Therapy with Integrated Boost to Prostate for High-risk Prostate Cancer a Randomized Phase 3 Trial Comparing Photons Vs. Protons","Inclusion Criteria:\n\n* Histologically verified localized\u002Flocally advanced prostate cancer T1-3bN0-1M0 (TNM 8th edition). A clinical T4 is allowed if it is because of invasion into the bladder neck.\n* Adenocarcinoma (mixed histology allowed as long as the adenocarcinoma component comprise more than 50%)\n* Indication for elective lymph node irradiation\n* PSA \\\u003C 100 ng\u002FmL\n* Age ≥18 years\n* Performance status 0-1\n* Life expectancy ≥ 10 years\n* Able to understand and comply with the treatment protocol\n* No evidence of inflammatory bowel disease Ability to adhere to procedures for study and follow-up\n* Signed informed consent to participate in the study\n\nExclusion Criteria:\n\n* No previous treatment for prostate cancer\n* Hip-prostheses\n* Other metal devices in the pelvic region (except fiducials)\n* Previous major abdominal\u002Frectal surgery\n* Any other malignancy the last five years except for basal or squamous cell skin cancer\n* Unable to understand patient information or comply with treatment and safety instructions\n* Unable to read and understand patient information due to cognitive disabilities or language (Danish).",{"count":52,"type":21},[24],"The purpose of this study is to assess late gastro-intestinal side-effects comparing proton therapy to photon therapy in high-risk prostate cancer patients receiving whole pelvic irradiation.",[332,31],[649,650,582],"Proton Therapy","High Risk","2025-03-05",{"date":630,"type":36},{"date":654,"type":36},"2022-03-01",{"date":656,"type":21},"2037-03-01",{"name":133,"class":43},7,""]